Singlife Launches Singapore's First Insurer-led Chronic Care Programme for Weight Management with Novo Singapore and HMI Medical

SINGAPORE, Oct. 15, 2026 /PRNewswire/ -- Leading homegrown financial services company Singlife has launched the Singlife Chronic Care Programme in partnership with Novo Nordisk Singapore and HMI Medical to support weight management. It is the first insurer-led initiative in Singapore designed to help customers manage obesity, improve health outcomes and address the risk of related chronic diseases.

The programme provides access to medically guided weight management, including a medical consultation and, where appropriate following assessment, prescription treatment. Available to all Singlife customers, the programme fee is S$289 per month, inclusive of GST, for customers assessed as suitable for the treatment and dosage covered by this rate. Treatment may include a prescription medicine registered with Singapore's Health Sciences Authority, with the attending doctor determining the appropriate treatment and dosage based on the individual's health needs and clinical suitability.

Treatment is generally intended for adults with an initial BMI of at least 30 kg/m², or between 27 and below 30 kg/m² with at least one weight-related comorbidity, and is used alongside a reduced-calorie diet and increased physical activity.

Singlife customers can book a weight management consultation via hmimedical.com/singlife-chronic-care-management, either through telemedicine or in person at participating HMI OneCare clinics islandwide. Following the assessment, the doctor will recommend treatment based on the individual's health needs and relevant clinical guidelines.

Improvements in weight and overall health will be considered when customers apply for a new policy or request a review of an existing policy, as part of Singlife's overall underwriting assessment.^[1]

Obesity is affecting a growing proportion of Singapore residents, with more than one in eight now living with the condition. Prevalence rose from 10.5% in 2019–2020 to 12.7% in 2023–2024.^[2] As obesity can increase the risk of conditions such as diabetes and cardiovascular disease, earlier access to doctor-led weight management can help people take action sooner, while potentially reducing the longer-term health and financial burden associated with chronic disease.

"Good health and financial wellbeing are closely linked. Chronic conditions can lead to ongoing medical expenses and place a significant financial strain on individuals and families," said Akhil Doegar, Group Head of Distribution, Singlife. "Through the Singlife Chronic Care Programme, we are helping customers take proactive steps to manage their health before more serious conditions develop. By improving access to obesity treatment, we are providing a better way to support customers on their journey to better health and make preventive care more accessible."

"Earlier action on obesity can make a real difference to people's long-term health. Novo Nordisk brings decades of experience in obesity care, but no organisation can improve population health alone. By bringing science, healthcare delivery and insurance together, this partnership can help more people get the support they need and strengthen the way obesity care is delivered in Singapore," said Vincent Siow, General Manager, Novo Singapore.

"Addressing obesity requires sustained, doctor-led care, but many people still face practical barriers such as cost, convenience or simply knowing where to start," said Dr Walter Lim, Chief Executive Officer, HMI Singapore. "This partnership helps address those barriers by making structured, evidence-based care easier to access through more than 25 clinics islandwide and telemedicine, while supporting patients with appropriate treatment over time and helping them better manage related metabolic risks such as diabetes, hypertension and high cholesterol."

-END-

About Singlife

Singlife is a leading homegrown financial services company that offers consumers a better way to financial freedom. We are headquartered in Singapore with a presence in the Philippines.  

Singlife meets diverse customer needs by offering a comprehensive suite of insurance products, including life and health, general insurance and investments, employee benefits, and financial advisory solutions.  

We achieve this through a differentiated, open-architecture distribution model and Singapore's largest network of financial advisers.   

A pioneer in the digital insurtech space, we offer digital solutions accessible through the Singlife App, MySinglife portal and the Group's investment platforms dollarDEX and GROW.

We are a key player in the employee benefits solutions space and are the exclusive insurance provider for the Ministry of Defence, Ministry of Home Affairs and Public Officers Group Insurance Scheme. We're also one of three government-approved long-term care insurance providers in Singapore.  

We take our commitment to achieving Net Zero seriously and are an official signatory of the United Nations Principles for Sustainable Insurance and the United Nations-supported Principles for Responsible Investment.  

Singlife was formed from the merger of Aviva Singapore and Singlife, originally an insurtech start up, in January 2022. Singlife is now a wholly owned subsidiary of Sumitomo Life, who acquired Singlife in 2024. We have over S$16 billion in assets as of 31 December 2025 and are rated "A" and "Baa1" by Fitch and Moody's respectively.  

Sumitomo Life was established in 1907 and is one of Japan's largest life insurance companies, with over US$300 billion in assets as of 30 September 2025. 

About Novo

Novo is the global healthcare company that believes lasting health starts now. For over a century, we've combined leading scientific expertise with a deep understanding of people's lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we're working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. In Singapore, Novo has been present since 1997 and has approximately 100 employees.

For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

About HMI Medical

Founded and headquartered in Singapore, HMI Medical is a leading regional healthcare group with over three decades of healthcare delivery across Singapore, Malaysia, Indonesia and Vietnam. The Group operates an integrated healthcare ecosystem spanning managed care, primary and specialist care, diagnostics, ambulatory services, hospitals and healthcare training. HMI Medical supports more than 4 million lives annually, with over 400 doctors and 3,000 employees. The Group is committed to making quality healthcare more accessible through connected, patient-centred care across the region. For more information, please visit www.hmimedical.com 

SOURCE Novo Nordisk